Tel Aviv

SUNDAY March 29- mONDAY MARCH 30, 2020

Tel Aviv, hilton

What is
PsyTech Summit?

PsyTech Summit is the global industry conference platform for the new wave of psychedelic medicine. With renewed research interest in LSD, MDMA, Ketamine and psilocybin, and a growing normalization after decades of stigma, psychedelics are the next therapeutic frontier.

Created by the team behind CannaTech, the PsyTech conference is poised to elevate the psychedelics conversation, foster normalization and accelerate innovation.

PsyTech debuts in Tel Aviv this March 29-30, and will bring together scientists, innovators, regulators, investors, and advocates from around the world to expand minds to the potential of psychedelic medicine.

Keynote Speakers

The leading global
Psychedelic Innovation Summit.

We are at the forefront of a new medical frontier.

Clinical trials at prestigious institutions like Johns Hopkins have been showing tremendous promise of psychedelic treatment in depression, anxiety, PTSD, and nicotine addiction.

As psychedelics move slowly through pharmaceutical regulatory systems, we must commit to studying their therapeutic potential in both pre-clinical and clinical settings.

Pre-clinical studies offer tight control of experimental parameters and help create a deeper understanding of the psychedelic experience.

Clinical research on psychedelic compounds is critical to developing treatment for some of society’s most challenging psychiatric conditions.

Psychedelics have enormous potential for treating some of the world’s most costly mental health issues. This potential raises some fascinating questions:

How can innovators navigate the complexities of bringing products and services to the modern medical market that are safe and evidence-based? 

How can pharmaceutical companies honor the spiritual and ecological aspects of the psychedelic experience? 

How can we create a model of investment and corporate pressure that successfully changes regulations to allow for continuing research and innovation?

While psychedelics have been used therapeutically throughout human history, modern research has been constrained as a result of prohibition and fear created by reckless recreational use.

After the 1960s, psychedelic drugs were classified under Schedule I, the most restrictively regulated drug schedule. Researchers were thus unable to study psychedelics compounds in any meaningful way.

In recent years, there have been some major advances in psychedelic drug law reform. Three major U.S. cities have decriminalized the use of psilocybin. Regulators, scientists, and businesses need to work together to overcome regulatory hurdles and advance critical, lifesaving research.

The evidence supporting the therapeutic use of psychedelics is simply too compelling to ignore.

apply now for the

psytech live pitch event

Are you seeking funding for a psychedelic business?

Apply here to pitch your psychedelic business concept live at PsyTech and for the chance to win an exclusive iCan prize package. Hundreds of high net worth investors seeking opportunities in the psychedelic industry.​
Click Here to Apply

The First-Ever Global Network
for Psychedelic Medicine





in the News

say about psychedelics

“Psychedelics are not a substitute for faith. They are a door to authentic faith, born of encountering directly the sacred dimension of everyday experience. This is not the only gate to that discovery, but it is the most ancient and universal, and potentially the most accessible to the majority of the human race.”
― Rick Doblin, Founder of MAPS
“In one of my early books I suggested that the potential significance of LSD and other psychedelics for psychiatry and psychology was comparable to the value the microscope has for biology or the telescope has for astronomy.”

― Stanislav Grof, Pioneer in the field of Psychedelic Therapy

“I’ve begun to wonder if perhaps these remarkable molecules might be wasted on the young, that they may have more to offer us later in life, after the cement of our mental habits and everyday behaviors has set.”

― Michael Pollan
Close Menu